Registration/Course Enrollment Open
IS9. Differentiating Atypical Antipsychotics in the Treatment of
Schizophrenia: From Theory to PracticeSupported by Pfizer
IS10. Fibromyalgia: Scientific Advances to Reduce the Burden of
IllnessSupported by Eli Lilly and Co.
IS11. Expanding the Neurobiological and Neuropsychological Foundation of
ADHD: Impact on Clinical PracticeSupported by Shire US Inc.
IS12. The Impact of Anxiety Disorders: A Case-Based Approach to
Improving Outcomes and Removing StigmaSupported by Cephalon
IS13. New Vistas in Treatment-Resistant DepressionSupported by
Publishers' Bookfair Open
Business Meeting and Forum (voting members only)
IS14. New Developments in Schizophrenia: From Neurobiology to PublicHealthSupported by Solvay Wyeth Pharmaceuticals
IS15. Vital Signs in Psychiatry: A Perspective on Sleep Across the Life
CycleSupported by Sepracor Inc.
IS16. Interrupting the Cycle of Vascular Disease and DepressionSupported by Forest Pharmaceuticals Inc.
IS17. Update on Insights From and Future Course of the Collaborative
Depression StudySupported by Wyeth Pharmaceuticals
IS18. Misdiagnosis of Bipolar II: Methods for Screening Patients at Risk
for Bipolar DisorderSupported by GlaxoSmithKline
IS19. Advances in the Understanding of the Dementia SpectrumSupported by Eisai Inc. and Pfizer Inc.
L1. The Challenge of Employment-Related Psychiatric EvaluationsLiza H. Gold, M.D., AAPL/APA's Manfred S. Guttmacher Award
Opening Session and Presidential Address
IS20. Alzheimer's Disease: Challenging the Practice ParadigmSupported by Forest Pharmacueticals Inc.
IS21. Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia:
Complete Results of the CATIE TrialSupported by Eli Lilly and
IS22. Pseudobulbar Affect: A Common Syndrome That Is Underrecognized,
Misdiagnosed, and UndertreatedSupported by Avanir
IS23. Advances in the Neurobiology and Therapeutics of ADHDSupported by Cephalon Inc.
IS24. Atypical Depression: Merging Evidence and Public PolicySupported by Bristol-Myers Squibb Co.
IS25. Insomnia From the Inside Out: From Neuroscience to Clinical
Experience to Public PolicySupported by Pfizer Inc. and Neurocrine